Business
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place May 11-15, 2026, in Boston, Massachusetts.
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., May 7, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place May 11-15, 2026, in Boston, Massachusetts.","length":260,"tagName":"p"},{"type":"text","content":"Oral Presentations:The oral presentations include an overview of recent advancements in production titer and product quality achieved through REGENXBIO's NAVXpress® manufacturing platform and an encore presentation of topline pivotal data from RGX-202, the company's next generation gene therapy program for Duchenne muscular dystrophy.","length":345,"tagName":"p"},{"type":"text","content":"Title: Advancing AAV manufacturability toolbox for early programs and beyondPresenter: Metewo Selase Kosi Enuameh, Ph.D., Associate Director, Vector Core at REGENXBIOPresentation: 266Session: AAV Critical Quality AttributesDate/Time: Thursday, May 14, 8:45 – 9:00am ETLocation: MCEC Room 204AB (Level 2)","length":308,"tagName":"p","attribs":{}},{"type":"text","content":"Title: RGX-202: Investigational gene therapy for Duchenne Muscular DystrophyPresenter: Aravindhan Veerapandiyan, M.D., Director of the Comprehensive Neuromuscular Program, PPMD Certified Duchenne Care Center, and Co-Director of the Muscular Dystrophy Association Care Center at Arkansas Children's HospitalPresentation: 506Session: In vivo clinical trials in eye and muscle disordersDate/Time: Friday, May 15, 4:30 – 4:45pm ETLocation: MCEC Room 210ABC (Level 2)","length":486,"tagName":"p","attribs":{}},{"type":"text","content":"Poster Presentations:These presentations demonstrate REGENXBIO's continued leadership in the discovery and advancement of next-generation gene therapies for rare and retinal diseases, and highlight the company's unique capsid engineering and translational capabilities.","length":278,"tagName":"p"},{"type":"text","content":"Title: NVG82, a capsid engineered for enhanced outer retinal gene transfer when administered in the suprachoroidal space, demonstrates superior on-target activity compared to AAV8Poster: 1031Presenter: Brendan Lilley, Ph.D., Director of Ophthalmology Research, REGENXBIOLocation: MCEC Exhibit and Poster Hall (Halls B2-C, Exhibit level)Date/Time: Tuesday, May 12, 5:00 – 6:30pm ET","l...